Ekso Bionics Announces Closing of $10 Million Public Offering
May 24 2019 - 4:01PM
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company,” “Ekso”
or “Ekso Bionics”), an industry leader in exoskeleton technology
for medical and industrial use, announced today the closing of its
previously announced underwritten public offering of 6,666,667
shares of its common stock and accompanying warrants to purchase
6,666,667 shares of its common stock, at a price to the public of
$1.50 per share and accompanying warrant to purchase one share of
common stock, for gross proceeds of $10.0 million before deducting
underwriters’ discounts, commissions and estimated offering
expenses. Each warrant has an exercise price of $2.00 per share and
will expire five years from the date of its issuance.
Cantor Fitzgerald & Co. acted as lead
book-running manager and SunTrust Robinson Humphrey, Inc. acted as
joint book-running manager for the offering.
The securities described above were offered by
the Company pursuant to a “shelf” registration statement on
Form S-3 (File No. 333-218517) relating to the public offering
of such securities, which was filed with the U.S. Securities and
Exchange Commission (the “SEC”) on June 6, 2017 and declared
effective by the SEC on June 16, 2017. A preliminary prospectus
supplement related to the offering was filed with the SEC on May
21, 2019 and a final prospectus supplement related to the offering
was filed with the SEC on May 24, 2019, all of which are available
on the SEC's website at http://www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the securities being offered may also be obtained by sending a
request to: Cantor Fitzgerald & Co., Attn: Capital Markets, 499
Park Avenue, 6th Floor, New York, NY 10022, or by email at
prospectus@cantor.com, or from SunTrust Robinson Humphrey, Inc.,
3333 Peachtree Road NE, 9th Floor, Atlanta, GA 30326, Attention:
Prospectus Department; email: strh.prospectus@suntrust.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy any of these
securities, nor shall there be any sale of these securities in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful, prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Ekso Bionics®
Ekso Bionics® is a leading developer of
exoskeleton solutions that amplify human potential by supporting or
enhancing strength, endurance, and mobility across medical and
industrial applications. Founded in 2005, the Company continues to
build upon its unparalleled expertise to design some of the most
cutting-edge, innovative wearable robots available on the market.
Ekso Bionics is the only exoskeleton company to offer technologies
that range from helping those with paralysis to stand up and walk,
to enhancing human capabilities on job sites across the globe. The
Company is headquartered in the Bay Area and is listed on the
Nasdaq Capital Market under the symbol EKSO.
Media Contact:
Glenn Silver 646-871-8485 eksobionics@lazarpartners.com
Investor Contact:
David Carey 212-867-1768 investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2024 to May 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From May 2023 to May 2024